BHB & CAR-T for Lymphomas

The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are receiving therapy for lymphoma with standard-of-care anti-CD19 CAR T-cells (CAR-T) to determine whether BHB supplementation is safe and tolerable in this patient population. Additionally, this study will determine whether BHB supplementation leads to changes the gut microbiome and peripheral blood mononuclear cells (PBMCs). BHB supplementation will be performed through oral administration of HVMN Ketone-IQ, a commercially available BHB supplement, with an active ingredient of R-

Trial Details

NCT ID
NCT06610344
Phase
NA
Sponsor
Abramson Cancer Center at Penn Medicine
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • R-1,3-Butanediol
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Age of 18 years or older
  • History of pathologically-confirmed large B-cell lymphoma (LBCL)
  • Planned treatment with a commercially available anti-CD19 CAR-T product (Yescarta or Kymriah)
  • Eligible for and with adequate organ function (investigator discretion) and performance status (ECOG PS 2 or less) for standard of care, anti-CD19 …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →